Article summary
For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin and LSD back into mainstream research, even as fundamental questions lingered about how these drugs work, which receptors truly matter, and whether therapeutic benefit must always be paired with an intense altered state. The post Two New Studies Are Rewriting the Rules of Psychedelic Drug Development appeared first on Microdose.
Continue to the original publication for the complete article.